セルボメッド
CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.86 | $0 | -$8M |
| 2025 Q4 | -0.87 | $0 | -$7M |
| 2025 Q3 | -0.84 | $322,569 | -$6M |
| 2025 Q2 | -0.70 | $0 | -$7M |
| 2025 Q1 | -0.56 | $0 | -$4M |
| 2024 Q4 | -0.77 | $0 | -$8M |
| 2024 Q3 |
| -0.55 |
| $0 |
| -$5M |
| 2024 Q2 | -0.27 | $0 | -$2M |